Editas Medicine Appoints Baisong Mei, MD, Ph.D., as Chief Medical Officer | Nation/World

CAMBRIDGE, Mass., July 18 11, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, MD, Ph.D., as Vice -Principal President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the company’s investigational drug portfolio across all therapeutic indications, including hematology, oncology and ophthalmology.

“We are delighted to have Baisong join our team. He brings to Editas a proven track record in advancing innovative medicines from IND acceptance to global regulatory approval. His extensive drug development experience and deep scientific knowledge make him an ideal partner for our research organization, enabling us to strategically advance our pipeline into and across the clinic,” said Gilmore O’Neill, MB, MMSc., President and Chief Executive Officer, Editas Médecine. “We are confident that Baisong’s leadership and expertise will help us achieve our near and long-term milestones as we advance our scientific insights through the drug development process and into marketed drugs to achieve our goal to provide patients with life-changing treatments.

“Editas Medicine’s mix of high-quality science, passion for transformative drug development and urgency to help patients attracted me to this role, and I am very excited to join the Editas team. “said Baisong Mei, MD, Ph.D., Chief Medical Officer, Editas Medicine. “At Editas, we have the opportunity to make a meaningful difference in the lives of patients, as we continue to advance our innovation and development efforts and work towards our goal of bringing multiple medicines to market. transformers.”

Dr. Mei brings to Editas more than 20 years of experience in the biotechnology and pharmaceutical industry, covering the entire life cycle of drug development in multiple disease areas, including hematology, neurology and others. diseases. During his career, Dr. Mei has demonstrated a strong track record in the clinical development and global regulatory approval of new drugs, including Alprolix®, Eloctate® and Onpattro®. He has led the clinical development of several new molecular entities (protein, siRNA, gene therapy and small molecule), from first-in-human studies to phase 3 studies (including pediatric studies) and regulatory approval in the States. US, EU, Japan, China, and other regions.

Prior to working in clinical development, Dr. Mei had a successful career in drug discovery research and CMC development where his leadership and inventions led to the discovery of an approved drug (Jivi®) and of a drug candidate with a recent BLA deposit (efanesoctocog alfa). Dr. Mei has also led several external strategic partnership collaborations for clinical development and drug discovery.

Dr. Mei joins Editas Medicine from Sanofi, where he held the position of senior global project manager in the field of rare diseases and rare blood disorders. His leadership has been essential to the clinical development pipeline of several rare diseases in hematology, neurology and nephrology. Prior to Sanofi, Dr. Mei was Therapeutic Area Manager for Clinical Development in Hematology at Biogen. In this role, he led programs in non-malignant hematology, including clinical programs in hemophilia, sickle cell disease and beta-thalassemia. Earlier in his career, Dr. Mei held leadership positions with increasing responsibilities in drug discovery research and CMC development at Biogen and Bayer.

Dr. Mei obtained his Ph.D. from the University of Toledo in Ohio and received his medical training at Bengbu Medical College and Wuhan University School of Medicine in China. Dr. Mei has also held postdoctoral fellowships at the University of California, San Francisco and the University of California, Berkeley. He was a faculty member of Wuhan University School of Medicine early in his career.

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust portfolio of treatments for people with serious illnesses all over the world. Editas Medicine aims to discover, develop, manufacture and commercialize transformative, sustainable and precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of the Harvard and Broad Institute Cas9 patent domains and the Broad Institute Cas12a patent domain for human medicines. For the latest scientific information and presentations, please visit www.editasmedicine.com.

Forward-looking statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect “, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “target”, “should”, “would” and similar expressions are intended to identify the forward-looking statements, although all forward-looking statements contain these identifying words, the Company may not actually achieve the plans, intentions or expectations disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements due to a variety of factors, including: the uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; the availability and timing of results from preclinical studies and clinical trials; whether the interim results of a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations regarding regulatory approvals to conduct trials or to commercialize products and the availability of sufficient funding for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure needs. These and other risks are described in greater detail under the heading “Risk Factors” included in the company’s most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission, as updated. by Editas Medicine’s subsequent filings with the Securities and Exchange Commission, and in other documents that the Company may file with the Securities and Exchange Commission in the future. All forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or other.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/deebd24c-85e3-4fe6-80bd-11263c6b5974

Contacts: Media Cristi Barnett (617) 401-0113 [email protected] Investors Ron Moldaver (617) 401-9052 [email protected]